Drugs targeting CD39 enzyme activity are of interest in immuno oncology as they help to maintain a pro-inflammatory environment thereby favoring anti-tumor immune responses that would otherwise be blunted by adenosine. This evidence concerns the gene ENTPD1 and neoplasm.